GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Zynex Inc (NAS:ZYXI) » Definitions » Operating Income

Zynex (ZYXI) Operating Income : $11.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Zynex Operating Income?

Zynex's Operating Income for the three months ended in Mar. 2024 was $0.5 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $11.0 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Zynex's Operating Income for the three months ended in Mar. 2024 was $0.5 Mil. Zynex's Revenue for the three months ended in Mar. 2024 was $46.5 Mil. Therefore, Zynex's Operating Margin % for the quarter that ended in Mar. 2024 was 1.13%.

Warning Sign:

Zynex Inc operating margin has been in a 5-year decline. The average rate of decline per year is -24.5%.

Zynex's 5-Year average Growth Rate for Operating Margin % was -24.50% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zynex's annualized ROC % for the quarter that ended in Mar. 2024 was 2.11%. Zynex's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.84%.


Zynex Operating Income Historical Data

The historical data trend for Zynex's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynex Operating Income Chart

Zynex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.07 10.25 22.37 22.94 10.78

Zynex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 2.71 5.49 2.30 0.53

Zynex Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zynex  (NAS:ZYXI) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zynex's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=2.1 * ( 1 - 23.08% )/( (77.718 + 75.673)/ 2 )
=1.61532/76.6955
=2.11 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Zynex's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2.1/( ( (15.629 + max(28.669, 0)) + (15.091 + max(27.437, 0)) )/ 2 )
=2.1/( ( 44.298 + 42.528 )/ 2 )
=2.1/43.413
=4.84 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(26.838 + 13.106 + 3.332) - (14.607 + 0 + 0)
=28.669

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(25.439 + 15.476 + 4.213) - (17.691 + 0 + 0)
=27.437

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Zynex's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=0.525/46.531
=1.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Zynex Operating Income Related Terms

Thank you for viewing the detailed overview of Zynex's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Zynex (ZYXI) Business Description

Traded in Other Exchanges
N/A
Address
9555 Maroon Circle, Englewood, CO, USA, 80112
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave and others.
Executives
Daniel J Moorhead officer: Chief Financial Officer 9777 PYRAMID CT, STE 100, ENGLEWOOD CO 80112
Anna Lucsok officer: See Remarks 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Thomas Sandgaard director, 10 percent owner, officer: President, CEO and Chairman 10506 KALAHARI CT., LONE TREE CO 80124
Neil Friery officer: See Remarks C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Joshua R. Disbrow director AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Barry D Michaels director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Michael D Cress director 3409 ESPERANZA CROSSING SUITE 7110, AUSTIN TX 78758
Sandgaard Holdings Llc 10 percent owner 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Giuseppe Papandrea officer: Chief Operating Officer C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112